Review of ocular immune privilege in the year 2010: Modifying the immune privilege of the eye

Ocular Immunology and Inflammation

Volumn 18, Issue 5, 2010, Pages 325-333

  Hori, Junko ^a   Vega, Jose L ^b   Masli, Sharmila ^c  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

ACAID; Corneal transplantation; Immune privilege

Indexed keywords

ANTERIOR EYE CHAMBER; CLINICAL PRACTICE; CORNEA ENDOTHELIUM; CORNEA TRANSPLANTATION; EYE INFLAMMATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; MICROENVIRONMENT; NERVE TRACT; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW;

AFFERENT PATHWAYS; ANIMALS; ANTERIOR CHAMBER; CELL TRANSPLANTATION; CORNEA; CORNEAL TRANSPLANTATION; EYE; GENE THERAPY; GRAFT SURVIVAL; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; NERVE FIBERS; OPHTHALMOLOGIC SURGICAL PROCEDURES; T-LYMPHOCYTES, REGULATORY; TISSUE TRANSPLANTATION;

EID: 77956857042     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.512696     Document Type: Review

References (89)

1. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29: 58-69.
2. Niederkorn J, Streilein JW, Shadduck JA. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci. 20: 355-363.
3. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci. 1993;34: 3347-3354.
4. Hori J, Joyce N, Streilein JW. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule. Invest Ophthalmol Vis Sci. 2000;41: 443-452.
5. Ng TF, Osawa H, Hori J, Young MJ, Streilein JW. Allogeneic neonatal neuronal retina grafts display partial immune privilege in the subcapsular space of the kidney. J Immunol. 2002;169: 5601-5606.
6. Wenkel H, Streilein JW. Evidence that retinal pigment epithelium functions as an immune-privileged tissue. Invest Ophthalmol Vis Sci. 2000;41: 3467-3473
7. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110: 1392-1403
8. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36: 2176-2185
9. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3: 879-889
10. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7: 354-359
11. Hori J, Streilein JW. Survival in high-risk eyes of epithelium-deprived orthotopic corneal allografts reconstituted in vitro with syngeneic epithelium. Invest Ophthalmol Vis Sci. 2003;44: 658-664
12. Zamiri P, Sugita S, Streilein JW. Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy. 2007;92: 86-93
13. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID), III: induction of ACAID depends upon intraocular transforming growth factor-beta. Eur J Immunol. 1992;22: 165-173
14. Wilbanks GA, Mammolenti M, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID), II: eye-derived cells participate in generating blood-borne signals that induce ACAID. J Immunol. 1991;146: 3018-3024
15. Wilbanks GA, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID), 1: evidence that an antigen-specific, ACAID-inducing, cellassociated signal exists in the peripheral blood. J Immunol. 1991;146: 2610-2617
16. Wilbanks GA, Streilein JW. Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Reg Immunol. 1992;4: 130-137
17. Williamson JS, Bradley D, Streilein JW. Immunoregulatory properties of bone marrow-derived cells in the iris and ciliary body. Immunology. 1989;67: 96-102
18. Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res. 2008;42: 41-50
19. Kosiewicz MM, Streilein JW. Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. J Immunol. 1996;157: 1905-1912
20. Wilbanks GA, Streilein JW. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen: evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology. 1990;71: 383-389
21. Zhang H, Yang P, Zhou H, Meng Q, Huang X. Involvement of Foxp3-expressing CD4+ CD25+ regulatory T cells in the development of tolerance induced by transforming growth factor-beta2-treated antigen-presenting cells. Immunology. 2008;124: 304-314
22. Saban DR, Cornelius J, Masli S, et al. The role of ACAID and CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens. Mol Vis. 2008;14: 2435-2442
23. Streilein JW, Bradley D, Sano Y, Sonoda Y. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci. 1996;37: 413-424
24. Taylor AW. Ocular immunosuppressive microenvironment. Chem Immunol Allergy. 2007;92: 71-85
25. Vega JL, Keino H, Masli S. Surgical denervation of ocular sympathetic afferents decreases local transforming growth factor-beta and abolishes immune privilege. Am J Pathol. 2009;175: 1218-1225
26. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol. 1977;25: 1-54
27. Sugita S, Futagami Y, Smith SB, Naggar H, Mochizuki M. Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta. Exp Eye Res. 2006;83: 1459-1471
28. Yoshida M, Kezuka T, Streilein JW. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege, 2: generation of TGF-beta-producing regulatory T cells. Invest Ophthalmol Vis Sci. 2000;41: 3862-3870
29. Yoshida M, Takeuchi M, Streilein JW. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege, 1: inhibition of T-cell activation in vitro by direct cell-to-cell contact. Invest Ophthalmol Vis Sci. 2000;41: 811-821
30. Sugita S, Streilein JW. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003;198: 161-171
31. Sugita S, Usui Y, Horie S, et al. T-cell suppression by Programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions. Invest Ophthalmol Vis Sci. 2009;50: 2862-2870
32. Sugita S, Horie S, Nakamura O, et al. Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells. J Immunol. 2008;181: 7525-7536
33. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci. 2006;47: 3912-3918
34. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci. 2005;46: 908-919
35. Vega JL, Saban DR, Carrier Y, Masli S, Weiner HL. Retinal pigment epithelial cells induce Foxp3+ regulatory T cells via membrane-bound TGF-β. Ocul Immunol Inflamm. (in press).
36. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18: 240-244
37. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270: 1189-1192
38. Hara Y, Okamoto S, Rouse B, Streilein JW. Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J Immunol. 1993;151: 5162-5171
39. Hara Y, Caspi RR, Wiggert B, Dorf M, Streilein JW. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J Immunol. 1992;149: 1531-1538
40. Masli S, Turpie B, Hecker KH, Streilein JW. Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties. J Immunol. 2002;168: 2264-2273
41. Takeuchi M, Alard P, Streilein JW. TGF-beta promotes immune deviation by altering accessory signals of antigenpresenting cells. J Immunol. 1998;160: 1589-1597
42. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol. 1997;27: 1648-1656
43. Ghafoori P, Yoshimura T, Turpie B, Masli S. Increased IkappaB alpha expression is essential for the tolerogenic property of TGF-beta-exposed APCs. FASEB J. 2009;23: 2226-2234
44. Masli S, Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology. 2009;127: 62-72
45. DOrazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol. 1998;160: 2089-2098
46. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol. 2006;18: 689-699
47. Ng TF, Turpie B, Masli S. Thrombospondin-1-mediated regulation of microglia activation after retinal injury. Invest Ophthalmol Vis Sci. 2009;50: 5472-5478
48. Saban DR, Bock F, Chauhan S, Masli S, Dana R. Thrombospondin-1 derived from antigen-presenting cells regulates their capacity for allosensitization. J Immunol. (in press)
49. Futagami Y, Sugita S, Vega J, et al. Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells. J Immunol. 2007;178: 6994-7005
50. Li X, Taylor S, Zegarelli B, Shen S, ORourke J, Cone RE. The induction of splenic suppressor T cells through an immuneprivileged site requires an intact sympathetic nervous system. J Neuroimmunol. 2004;153: 40-49
51. Regenbogen LS, Naveh-Floman N. Glaucoma in Fuchs heterochromic cyclitis associated with congenital Horners syndrome. Br J Ophthalmol. 1987;71: 844-849
52. Diesenhouse MC, Palay DA, Newman NJ, To K, Albert DM. Acquired heterochromia with horner syndrome in two adults. Ophthalmology. 1992;99: 1815-1817
53. Aggarwal RK, Luck J, Coster DJ. 1994. Horners syndrome and Fuchs heterochromic uveitis. Br J Ophthalmol. 1994; 78: 949
54. Taylor AW, Yee DG. 2003. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 2003;44: 2644-2649
55. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39: 1372-1378
56. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. J Leukoc Biol. 2006;79: 1093-1104
57. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117: 289-296
58. Streilein JW, Toews GB, Bergstresser PR. Corneal allografts fail to express Ia antigens. Nature. 1979;282: 326-327
59. Sosnova M, Bradl M, Forrester JV. CD34+ corneal stromal cells are bone marrow-derived and express hemopoietic stem cell markers. Stem Cells. 2005;23: 507-515
60. Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci. 2002;43: 639-646
61. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci. 1984;25: 519-524
62. Wang HM, Kaplan HJ, Chan WC, Johnson M. The distribution and ontogeny of MHC antigens in murine ocular tissue. Invest Ophthalmol Vis Sci. 1987;28: 1383-1389
63. Treseler PA, Sanfilippo F. The expression of major histocompatibility complex and leukocyte antigens by cells in the rat cornea. Transplantation. 1986; 41: 248-252
64. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice: evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54: 694-704
65. Streilein JW, Arancibia-Caracamo C, Osawa H. The role of minor histocompatibility alloantigens in penetrating keratoplasty. Dev Ophthalmol. 36: 74-88
66. Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol. 2003;150: 1727-1734
67. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci. 1996;37: 2700-2707 (Pubitemid 27026555)
68. Sonoda KH, Taniguchi M, Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1dreactive NKT cells. J Immunol. 2002;168: 2028-2034
69. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun. 2000;267: 257-261
70. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J Leukoc Biol. 2002;72: 946-952
71. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160: 5693-5696
72. Kennedy MC, Rosenbaum JT, Brown J, et al. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J Clin Invest. 1995;95: 82-88
73. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci. 2000;41: 4195-4202
74. Hori J, Joyce NC, Streilein JW. Immune privilege and immunogenicity reside among different layers of the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41: 3032-3042
75. Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177: 5928-5935
76. Hori J, Wang MC, Taniguchi H, et al. GITR ligand-mediated local expansion of regulatory T cells contributes to immune privilege of corneal allografts. Invest Ophthalmol Vis Sci. 2010; (in press)
77. Hori J. Molecular mechanisms of immune suppressive microenvironment in the cornea. Cornea. 2009; 28: S58-S64
78. Hori J, Streilein JW. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 2001;42: 720-726 (Pubitemid 32206914)
79. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol. 2008;126: 71-77
80. Chen L, Hamrah P, Cursiefen C, et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 2004;10: 813-815
81. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009;15: 1023-1030
82. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci. 2001;42: 1568-1573
83. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci. 2002; E 43: 1095-1103.
84. Klebe S, Coster DJ, Sykes PJ, et al. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol. 2005;175: 2219-2226
85. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol. 2006;36: 690-700
86. Gong N, Pleyer U, Vogt K, et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci. 2007;48: 1043-1052
87. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation. 2001;71: 1214-1220
88. Stuart PM, Pan F, Yin X, Haskova Z, Plambeck S, Ferguson TA. Effect of metalloprotease inhibitors on corneal allograft survival. Invest Ophthalmol Vis Sci. 2004;45: 1169-1173
89. Keino H, Watanabe T, Sato Y, Okada AA. Anti-inflammatory effect of retinoic acid on experimental autoimmune uveoretinitis. Br J Ophthalmol. 2010;94: 802-807